Recent Updates — EBS
Emergent BioSolutions announced that Chief Financial Officer Richard Lindahl will step down effective December 31, 2026. Vice President and Treasurer Frank Vargo has been appointed Interim Chief Financial Officer beginning January 1, 2027. Lindahl will serve as a senior executive advisor through March 31, 2027 to assist with the transition. The Board approved interim compensation for Vargo of an additional $3,850 per pay period on top of his current base salary. Emergent BioSolutions develops and manufactures vaccines and medical countermeasures against biological threats.
Emergent BioSolutions Inc. filed a Form 8-K to furnish an investor presentation by CEO Joseph C. Papa at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company announced a restructuring plan expected to yield $40 million in annualized savings through workforce reductions of 90 roles and facility consolidations. Financially, Emergent reported MCM segment Q2 2026 revenue of $168 million and secured government contract modifications totaling approximately $117.2 million for ACAM2000® and BAT® products. The company also repurchased $75 million in unsecured bonds in the second quarter and reauthorized a $50 million share repurchase program with $37.5 million remaining. Full-year 2026 revenue guidance was revised downward to $645–$675 million, with adjusted EBITDA projected at $130–$150 million. Emergent BioSolutions Inc. operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures for public health threats and opioid overdose treatments.
On August 18, 2026, Emergent BioSolutions Inc. received Modification No. 21 to its BARDA AV7909 Contract, securing an additional $24 million in funding for the procurement of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). This contract modification supports anthrax preparedness efforts and builds upon previous government agreements, including a recent delivery order valued at up to $21.5 million for BioThrax supplies. The company operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures against biological threats.
Emergent BioSolutions Inc. reported second quarter 2026 total revenues of $234.3 million, a 66% increase year-over-year, driven by accelerated U.S. government contract modifications for ACAM2000 and BAT products. The company posted a net loss of $180.2 million due to a $191.3 million non-cash impairment charge related to its NARCAN asset group, while adjusted EBITDA reached $96.5 million. Management announced a restructuring plan targeting approximately $40 million in annualized savings through the elimination of roughly 93 employee positions and the closure of wet laboratories in Gaithersburg, Maryland, with estimated charges of $10 million to $11.5 million expected in the second half of 2026. Concurrently, Chief Medical Officer Simon Lowry is departing effective August 19, 2026, and Stephanie Duatschek has been appointed Executive Vice President, Chief Growth Officer. The company revised its full-year 2026 revenue guidance downward to $645–$675 million from a previous range of $720–$760 million. Emergent BioSolutions operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures for biodefense and commercial opioid overdose treatments.
Emergent BioSolutions Inc. received a $52.7 million contract modification from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to supply ACAM2000 smallpox vaccine doses, ancillaries, and diluent replacement lots. The modification exercises the seventh option year of a 10-year contract. Emergent BioSolutions Inc. operates in the biopharmaceutical industry, providing medical countermeasures and medical products for public health emergencies.